CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T（CAR-T）细胞是复发/难治性（R/R）非霍奇金淋巴瘤（NHL）、急性淋巴细胞白血病和多发性骨髓瘤患者的一种治疗选择。迄今为止，弥漫性大B细胞淋巴瘤（DLBCL）、套细胞淋巴瘤（MCL）、滤泡性淋巴瘤（FL）和慢性淋巴细胞白血病（CLL）已成功通过靶向CD19抗原的CAR-T 细胞进行治疗。然而，当经过多线治疗后R/R疾病仍持续存在时，这些疾病患者常被转诊至移植中心接受异基因干细胞移植（ALLO-SCT）。ALLO-SCT和CAR-T 细胞具有共同的作用机制，即诱导T细胞（以及移植后的其他细胞）对淋巴瘤细胞的免疫效应，但它们在若干其他特征上存在差异。这些差异决定了每种疗法在治疗算法中具有独特的定位。本文中，我们分析了侵袭性淋巴瘤（大B细胞淋巴瘤和MCL）患者接受ALLO-SCT和CAR-T 细胞治疗后的结果，以确定这两种免疫疗法应采用的理想应用场景。
Chimeric antigen receptor T (CAR-T) cells are a treatment option for patients with relapse/refractory (R/R) non-Hodgkin lymphoma (NHL), acute lymphoid leukemia and multiple myeloma. To date, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) have been successfully treated with CAR-T cells directed against the CD19 antigen.
However, when R/R disease persists after several treatment lines, patients with these diseases are often referred to transplantation centres to receive allogeneic stem cell transplantation (ALLO-SCT). ALLO-SCT and CAR-T cells share mechanism of actions, inducing immune effects of T -cells (and other cells after transplantation) against lymphoma cells, but they differ in several other characteristics.
These differences justify unique positioning of each therapy within treatment algorithms. In this paper, we analyzed the results obtained after ALLO-SCT and CAR-T-cell therapy in patients with aggressive lymphomas (large B-cell lymphoma and MCL) to identify the ideal scenarios in which these 2 immunological therapies should be employed.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
